Skip to main content
Clinical Trials/NCT04290559
NCT04290559UnknownNot Applicable

Long-term Monitoring After Persistent Atrial Fibrillation Ablation and Correlation to Quality of Life

Newmarket Electrophysiology Research Group Inc1 site in 1 country200 target enrollmentStarted: September 10, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
AF burden correlated with change in QOL.

Study Overview

Brief Summary

The primary objective of this study is to determine the atrial fibrillation burden reduction, or absolute atrial fibrillation burden, associated with improvement in quality of life in patients undergoing ablation of persistent atrial fibrillation.

Detailed Description

Atrial fibrillation (AF) is associated with a higher risk of stroke, heart failure and deterioration in patients' quality of life and it also has great effect on health care resource utilization due to increasing morbidity and mortality. Catheter ablation has shown to improve patients' quality of life (QOL), even in those who undergo a repeat procedure, equalizing healthy population and lowering subsequent health care resource utilization.

Success rates are usually based on an endpoint of total elimination of AF, typically absence of any AF recurrence >30 seconds. While this is a high standard for clinical trial reporting, it does not necessarily measure the "clinical" success, since many patients will experience significant reduction in their AF burden with accompanying improvement in their functional status despite having ongoing brief recurrences of AF.

This is a prospective non-randomized, single-arm, cohort study. 200 patients with persistent atrial fibrillation undergoing catheter ablation will be enroled. AF burden post procedure will be evaluated with continuous monitoring with an implantable loop recorder (ILR) to assess recurrences and AF burden. QOL will be measured using the CCS-SAF severity scale, SF-36 and AFEQT scales pre-ablation and at 12 and 24 months.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age > 18 years
  • Patients undergoing first-time or redo AF ablation.
  • Persistent or long-standing persistent AF
  • Symptomatic atrial fibrillation
  • Willing and able to provide informed consent.
  • Willing and able to set up and utilize MyCareLink® home monitor and be remotely monitored
  • Atrial fibrillation burden equal or more than 80% prior to the ablation

Exclusion Criteria

  • Paroxysmal AF
  • If the patient has had a cardioversion within 2 months of the ablation
  • Patients with contraindication to oral or intravenous anticoagulation.
  • Contraindication to implantation of an ILR

Outcomes

Primary Outcomes

AF burden correlated with change in QOL.

Time Frame: 12 months, 24 months

AF burden change and absolute AF burden correlated with change in QOL mesured at 12 and 24 months after the AF ablation

Secondary Outcomes

  • Freedom of atrial arrhythmia(12 months, 24 months)
  • Incidence of silent AF recurrences(12 months, 24 months)
  • Economic evaluation(12 months, 24 months)
  • Impact of antiarrhythmic treatment(12 months)

Investigators

Sponsor
Newmarket Electrophysiology Research Group Inc
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials